Pernod Ricard SA (OTCMKTS:PDRDY – Get Rating) has been given a consensus recommendation of “Hold” by the eleven research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $238.67.
Several research firms have commented on PDRDY. Credit Suisse Group increased their price target on shares of Pernod Ricard from €215.00 ($231.18) to €217.00 ($233.33) and gave the company a “neutral” rating in a research report on Friday, April 1st. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Pernod Ricard from €245.00 ($263.44) to €256.00 ($275.27) in a research report on Wednesday, January 19th. Finally, Barclays increased their price objective on shares of Pernod Ricard from €233.00 ($250.54) to €243.00 ($261.29) in a research report on Wednesday, January 5th.
PDRDY stock opened at $47.12 on Thursday. The firm has a 50-day simple moving average of $47.12 and a two-hundred day simple moving average of $46.93. Pernod Ricard has a one year low of $34.68 and a one year high of $47.39.
Pernod Ricard SA engages in the manufacture of wines, spirits, and non-alcoholic beverages. The firm offers products under the brands Absolut Vodka, Chivas Regal, Ballantine’s, Beefeater, Jameson, Kahlúa, Malibu, Ricard, Havana Club, Martell, Cognac, The Glenlivet, G.H. Mumm, Perrier-Jouët, Royal Salute, Brancott Estate, Graffigna, Campo Viejo, Jacob’s Creek, Kenwood, Pastis 51, 100 Pipers, ArArAt, Becherovka, Blenders Pride, Clan Campbell, Imperial, Seagram’s Imperial Blue, Olmeca, Passport Scotch, Amaro Ramazzotti, Ruavieja, Royal Stag, Seagram’s Gin, Something Special, Suze, Wiser’s, and Wyborowa.
- Get a free copy of the StockNews.com research report on Pernod Ricard (PDRDY)
- Google Upgraded Ahead Of Earnings
- Highly Valued Abbot Laboratories Could Move Lower
- Baker Hughes, Another Buy-The-Dip Opportunity In Oilfield Services
- Netflix (NASDAQ: NFLX) Falls Back to 2018 Levels
- Is Turning Point Therapeutics Stock at a Turning Point?
Receive News & Ratings for Pernod Ricard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernod Ricard and related companies with MarketBeat.com's FREE daily email newsletter.